Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 7/20 | 0.40 |
| ▸ | CSF1R | P07333 | 6/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.38 |
| ▸ | KDR | P35968 | 5/20 | 0.38 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723743 | 0.86 | GCK (0.49) | GCKCSF1RPDGFRBKDRFLT3 | |
| SCHEMBL1727457 | 0.82 | GCK (0.55) | GCK | |
| SCHEMBL1725087 | 0.77 | GCK (0.56) | GCK | |
| SCHEMBL1722210 | 0.76 | GCK (0.43) | GCKMAPTGAAALDH1A1NPSR1 | |
| SCHEMBL1722063 | 0.76 | GCK (0.49) | GCKMAPTGAAALDH1A1NPSR1 | |
| SCHEMBL1726203 | 0.75 | GCK (0.49) | GCK | |
| SCHEMBL1724799 | 0.74 | HSD17B2 (0.47) | GCKPDGFRBMAPTGAANPSR1 | |
| SCHEMBL1722819 | 0.73 | GCK (0.52) | GCKMAPTNPC1 | |
| SCHEMBL1721840 | 0.72 | GCK (0.49) | GCKCSF1RPDGFRBKDRFLT3 | |
| SCHEMBL1723440 | 0.72 | GCK (0.46) | GCKMAPTGAATSHRNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406230-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | Pfizer Inc. (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | CORBETT JEFFREY W (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010103438-A1 | SUBSTITUTED INDAZOLE AMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | PFIZER INC. (US) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319379-A1 | Substituted Indazole Amides And Their Use As Glucokinase Activators | GCKR, GCK, GALK1 | GCK 2/4885CSF1R 1794/4885PDGFRB 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.